Download PDF
Semin Respir Crit Care Med 2020; 41(04): 470-479
DOI: 10.1055/s-0040-1709992
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Staphylococcus aureus Pneumonia in the Community

Hangyong He
1   Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
,
Richard G. Wunderink
2   Department of Medicine, Division of Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
10 June 2020 (online)

    Permissions and Reprints

Abstract

Staphylococcus aureus is an emergent etiology of community-acquired pneumonia (CAP) over the past 2 decades, with severe community-acquired pneumonia (SCAP) caused by methicillin-resistant S. aureus (MRSA) leading to critical illness and death. S. aureus colonization is associated with a high incidence of pneumonia. Panton-Valentine leukocidin (PVL) is one of the most important virulence factors of S. aureus associated with serious complications. In recent years, community-associated MRSA (CA-MRSA) clones that caused infections in young adults and healthy individuals with no exposure to health care settings and no classical risk factors have emerged. Clinical features at admission including concurrent influenza infection, hemoptysis, multilobar infiltrates, and neutropenia should suggest S. aureus CAP. Sputum Gram stains, cultures (or tracheobronchial aspirates or bronchoalveolar lavage in mechanically ventilated patients), polymerase chain reaction (nasopharyngeal or oropharyngeal or lower respiratory tract specimens), and two sets of blood cultures should be obtained from patients presenting with severe S. aureus CAP. For CAP due to methicillin-susceptible S. aureus, first-line therapy is usually cefazolin, oxacillin, or ceftaroline. For CA-MRSA pneumonia, linezolid is recommended. If vancomycin or teicoplanin are used, combination with clindamycin or rifampicin should be considered in cases of PVL-positive MRSA CAP.

Keywords

Staphylococcus aureus - community-acquired pneumonia - methicillin-resistant S. aureus - Panton-Valentine leukocidin
 

  • References

  • 1 Moran GJ, Krishnadasan A, Gorwitz RJ. , et al; EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54 (08) 1126-1133
    CrossrefPubMedGoogle Scholar
  • 2 Francis JS, Doherty MC, Lopatin U. , et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40 (01) 100-107
    CrossrefPubMedGoogle Scholar
  • 3 Hageman JC, Uyeki TM, Francis JS. , et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12 (06) 894-899
    CrossrefPubMedGoogle Scholar
  • 4 Kallen AJ, Brunkard J, Moore Z. , et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53 (03) 358-365
    CrossrefPubMedGoogle Scholar
  • 5 van Belkum A, Melles DC, Nouwen J. , et al. Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus . Infect Genet Evol 2009; 9 (01) 32-47
    CrossrefPubMedGoogle Scholar
  • 6 Wertheim HF, Melles DC, Vos MC. , et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5 (12) 751-762
    CrossrefPubMedGoogle Scholar
  • 7 Wunderink RG. How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?. Infect Dis Clin North Am 2013; 27 (01) 177-188
    CrossrefPubMedGoogle Scholar
  • 8 Bogaert D, van Belkum A, Sluijter M. , et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363 (9424): 1871-1872
    CrossrefPubMedGoogle Scholar
  • 9 Wertheim HF, Vos MC, Ott A. , et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004; 364 (9435): 703-705
    CrossrefPubMedGoogle Scholar
  • 10 Creech II CB, Kernodle DS, Alsentzer A, Wilson C, Edwards KM. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J 2005; 24 (07) 617-621
    CrossrefPubMedGoogle Scholar
  • 11 Gorwitz RJ, Kruszon-Moran D, McAllister SK. , et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197 (09) 1226-1234
    CrossrefPubMedGoogle Scholar
  • 12 Tilahun B, Faust AC, McCorstin P, Ortegon A. Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus . Am J Crit Care 2015; 24 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 13 Paling FP, Wolkewitz M, Bode LGM. , et al. Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia. Clin Microbiol Infect 2017; 23 (01) 49.e9-49.e14
    PubMedGoogle Scholar
  • 14 Grousd JA, Rich HE, Alcorn JF. Host-pathogen interactions in gram-positive bacterial pneumonia. Clin Microbiol Rev 2019; 32 (03) 32
    CrossrefPubMedGoogle Scholar
  • 15 von Hoven G, Qin Q, Neukirch C, Husmann M, Hellmann N. Staphylococcus aureus α-toxin: small pore, large consequences. Biol Chem 2019; 400 (10) 1261-1276
    PubMedGoogle Scholar
  • 16 Wunderink RG, Yin Y. Antibiotic resistance in community-acquired pneumonia pathogens. Semin Respir Crit Care Med 2016; 37 (06) 829-838
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Tam K, Torres VJ. Staphylococcus aureus secreted toxins and extracellular enzymes. Microbiol Spectr 2019; 7 (02) 7
    CrossrefPubMedGoogle Scholar
  • 18 Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50 (01) 59-69
    CrossrefPubMedGoogle Scholar
  • 19 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39 (03) 309-317
    CrossrefPubMedGoogle Scholar
  • 20 Liu C, Bayer A, Cosgrove SE. , et al; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52 (03) e18-e55
    CrossrefPubMedGoogle Scholar
  • 21 Wunderink RG, Niederman MS, Kollef MH. , et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54 (05) 621-629
    CrossrefPubMedGoogle Scholar
  • 22 Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect 2013; 43 (11-12): 451-455
    CrossrefPubMedGoogle Scholar
  • 23 Chastre J, Wolff M, Fagon JY. , et al; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290 (19) 2588-2598
    CrossrefPubMedGoogle Scholar
  • 24 Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003; 45 (04) 279-285
    CrossrefPubMedGoogle Scholar
  • 25 Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368 (9538): 874-885
    CrossrefPubMedGoogle Scholar
  • 26 Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus . Clin Infect Dis 2011; 52 (09) 1156-1163
    CrossrefPubMedGoogle Scholar
  • 27 Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in Staphylococcus aureus . Annu Rev Biochem 2015; 84: 577-601
    CrossrefPubMedGoogle Scholar
  • 28 Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus . Infect Genet Evol 2008; 8 (06) 747-763
    CrossrefPubMedGoogle Scholar
  • 29 Herold BC, Immergluck LC, Maranan MC. , et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279 (08) 593-598
    CrossrefPubMedGoogle Scholar
  • 30 Tristan A, Bes M, Meugnier H. , et al. Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007; 13 (04) 594-600
    CrossrefPubMedGoogle Scholar
  • 31 Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice?. Int J Antimicrob Agents 2009; 34 (Suppl. 01) S15-S19
    PubMedGoogle Scholar
  • 32 Robinson DA, Kearns AM, Holmes A. , et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet 2005; 365 (9466): 1256-1258
    CrossrefPubMedGoogle Scholar
  • 33 Lina G, Piémont Y, Godail-Gamot F. , et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29 (05) 1128-1132
    CrossrefPubMedGoogle Scholar
  • 34 Groom AV, Wolsey DH, Naimi TS. , et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286 (10) 1201-1205
    CrossrefPubMedGoogle Scholar
  • 35 Hidron AI, Low CE, Honig EG, Blumberg HM. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009; 9 (06) 384-392
    CrossrefPubMedGoogle Scholar
  • 36 Moran GJ, Krishnadasan A, Gorwitz RJ. , et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355 (07) 666-674
    CrossrefPubMedGoogle Scholar
  • 37 Gonzalez BE, Rueda AM, Shelburne III SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27 (10) 1051-1056
    CrossrefPubMedGoogle Scholar
  • 38 Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J Antimicrob Chemother 2007; 60 (06) 1258-1263
    CrossrefPubMedGoogle Scholar
  • 39 Vandenesch F, Naimi T, Enright MC. , et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9 (08) 978-984
    CrossrefPubMedGoogle Scholar
  • 40 Adler A, Temper V, Block CS, Abramson N, Moses AE. Panton-Valentine leukocidin-producing Staphylococcus aureus . Emerg Infect Dis 2006; 12 (11) 1789-1790
    CrossrefPubMedGoogle Scholar
  • 41 Saeed K, Gould I, Esposito S. , et al; International Society of Chemotherapy. Panton-Valentine leukocidin-positive Staphylococcus aureus: a position statement from the International Society of Chemotherapy. Int J Antimicrob Agents 2018; 51 (01) 16-25
    CrossrefPubMedGoogle Scholar
  • 42 Rasigade JP, Laurent F, Lina G. , et al. Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981-2007. J Infect Dis 2010; 201 (10) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 43 Otokunefor K, Sloan T, Kearns AM, James R. Molecular characterization and Panton-Valentine leucocidin typing of community-acquired methicillin-sensitive Staphylococcus aureus clinical isolates. J Clin Microbiol 2012; 50 (09) 3069-3072
    CrossrefPubMedGoogle Scholar
  • 44 Monecke S, Slickers P, Ellington MJ, Kearns AM, Ehricht R. High diversity of Panton-Valentine leukocidin-positive, methicillin-susceptible isolates of Staphylococcus aureus and implications for the evolution of community-associated methicillin-resistant S. aureus . Clin Microbiol Infect 2007; 13 (12) 1157-1164
    CrossrefPubMedGoogle Scholar
  • 45 Self WH, Wunderink RG, Williams DJ. , et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis 2016; 63 (03) 300-309
    CrossrefPubMedGoogle Scholar
  • 46 Aliberti S, Reyes LF, Faverio P. , et al; GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 2016; 16 (12) 1364-1376
    CrossrefPubMedGoogle Scholar
  • 47 Jain S, Self WH, Wunderink RG. , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
    CrossrefPubMedGoogle Scholar
  • 48 Rice TW, Rubinson L, Uyeki TM. , et al; NHLBI ARDS Network. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40 (05) 1487-1498
    CrossrefPubMedGoogle Scholar
  • 49 Jacquot A, Luyt CE, Kimmoun A, Levy B, Baux E. ; Fluvalentine Study group. Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine leucocidin positive Staphylococcus aureus in intensive care units: a retrospective nationwide study. Intensive Care Med 2019; 45 (09) 1312-1314
    CrossrefPubMedGoogle Scholar
  • 50 Torres A, Chalmers JD, Dela Cruz CS. , et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019; 45 (02) 159-171
    CrossrefPubMedGoogle Scholar
  • 51 Kazakova SV, Hageman JC, Matava M. , et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352 (05) 468-475
    CrossrefPubMedGoogle Scholar
  • 52 Charlebois ED, Bangsberg DR, Moss NJ. , et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002; 34 (04) 425-433
    CrossrefPubMedGoogle Scholar
  • 53 Begier EM, Frenette K, Barrett NL. , et al; Connecticut Bioterrorism Field Epidemiology Response Team. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39 (10) 1446-1453
    CrossrefPubMedGoogle Scholar
  • 54 Bratu S, Eramo A, Kopec R. , et al. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis 2005; 11 (06) 808-813
    CrossrefPubMedGoogle Scholar
  • 55 Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11 (06) 928-930
    CrossrefPubMedGoogle Scholar
  • 56 Gillet Y, Issartel B, Vanhems P. , et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359 (9308): 753-759
    CrossrefPubMedGoogle Scholar
  • 57 Gillet Y, Vanhems P, Lina G. , et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45 (03) 315-321
    CrossrefPubMedGoogle Scholar
  • 58 Vardakas KZ, Matthaiou DK, Falagas ME. Comparison of community-acquired pneumonia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus producing the Panton-Valentine leukocidin. Int J Tuberc Lung Dis 2009; 13 (12) 1476-1485
    PubMedGoogle Scholar
  • 59 Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138 (01) 130-136
    CrossrefPubMedGoogle Scholar
  • 60 Van De Griend P, Herwaldt LA, Alvis B. , et al. Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA. Emerg Infect Dis 2009; 15 (10) 1582-1589
    CrossrefPubMedGoogle Scholar
  • 61 McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77-104
    CrossrefPubMedGoogle Scholar
  • 62 Fritz CQ, Edwards KM, Self WH. , et al. Prevalence, risk factors, and outcomes of bacteremic pneumonia in children. Pediatrics 2019; 144 (01) 144
    PubMedGoogle Scholar
  • 63 Smith MN, Brotherton AL, Lusardi K, Tan CA, Hammond DA. Systematic review of the clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening for MRSA pneumonia. Ann Pharmacother 2019; 53 (06) 627-638
    CrossrefPubMedGoogle Scholar
  • 64 Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother 2014; 58 (02) 859-864
    CrossrefPubMedGoogle Scholar
  • 65 Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis 2018; 67 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 66 Rimawi RH, Ramsey KM, Shah KB, Cook PP. Correlation between methicillin-resistant Staphylococcus aureus nasal sampling and S. aureus pneumonia in the medical intensive care unit. Infect Control Hosp Epidemiol 2014; 35 (05) 590-593
    CrossrefPubMedGoogle Scholar
  • 67 Gadsby NJ, Russell CD, McHugh MP. , et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016; 62 (07) 817-823
    CrossrefPubMedGoogle Scholar
  • 68 Wolff BJ, Bramley AM, Thurman KA. , et al. Improved detection of respiratory pathogens by use of high-quality sputum with TaqMan array card technology. J Clin Microbiol 2016; 55 (01) 110-121
    PubMedGoogle Scholar
  • 69 Leone M, Malavieille F, Papazian L. , et al; AzuRea Network. Routine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia. Crit Care 2013; 17 (04) R170
    CrossrefPubMedGoogle Scholar
  • 70 Strålin K, Ehn F, Giske CG. , et al. The IRIDICA PCR/electrospray ionization-mass spectrometry assay on bronchoalveolar lavage for bacterial etiology in mechanically ventilated patients with suspected pneumonia. PLoS One 2016; 11 (07) e0159694
    CrossrefPubMedGoogle Scholar
  • 71 Paonessa JR, Shah RD, Pickens CI. , et al. Rapid detection of methicillin-resistant Staphylococcus aureus in BAL: a pilot randomized controlled trial. Chest 2019; 155 (05) 999-1007
    CrossrefPubMedGoogle Scholar
  • 72 Metlay JP, Waterer GW, Long AC. , et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
    CrossrefPubMedGoogle Scholar
  • 73 Yan ST, Sun LC, Jia HB, Gao W, Yang JP, Zhang GQ. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med 2017; 35 (04) 579-583
    CrossrefPubMedGoogle Scholar
  • 74 Leli C, Ferranti M, Moretti A, Al Dhahab ZS, Cenci E, Mencacci A. Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections. Dis Markers 2015; 2015: 701480
    PubMedGoogle Scholar
  • 75 Brodská H, Malíčková K, Adámková V, Benáková H, Šťastná MM, Zima T. Significantly higher procalcitonin levels could differentiate gram-negative sepsis from gram-positive and fungal sepsis. Clin Exp Med 2013; 13 (03) 165-170
    CrossrefPubMedGoogle Scholar
  • 76 Thomas-Rüddel DO, Poidinger B, Kott M, Weiss M, Reinhart K, Bloos F. ; MEDUSA study group. Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia. Crit Care 2018; 22 (01) 128
    CrossrefPubMedGoogle Scholar
  • 77 Self WH, Wunderink RG, Jain S, Edwards KM, Grijalva CG. ; Etiology of Pneumonia in the Community (EPIC) Study Investigators. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2018; 66 (10) 1640-1641
    CrossrefPubMedGoogle Scholar
  • 78 Stockmann C, Ampofo K, Killpack J. , et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc 2018; 7 (01) 46-53
    CrossrefPubMedGoogle Scholar
  • 79 Gelfer G, Leggett J, Myers J, Wang L, Gilbert DN. The clinical impact of the detection of potential etiologic pathogens of community-acquired pneumonia. Diagn Microbiol Infect Dis 2015; 83 (04) 400-406
    CrossrefPubMedGoogle Scholar
  • 80 Cuquemelle E, Soulis F, Villers D. , et al; A/H1N1 REVA-SRLF Study Group. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med 2011; 37 (05) 796-800
    CrossrefPubMedGoogle Scholar
  • 81 Christ-Crain M, Jaccard-Stolz D, Bingisser R. , et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363 (9409): 600-607
    CrossrefPubMedGoogle Scholar
  • 82 Christ-Crain M, Stolz D, Bingisser R. , et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174 (01) 84-93
    CrossrefPubMedGoogle Scholar
  • 83 Bouadma L, Luyt CE, Tubach F. , et al; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375 (9713): 463-474
    CrossrefPubMedGoogle Scholar
  • 84 Schuetz P, Briel M, Christ-Crain M. , et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012; 55 (05) 651-662
    CrossrefPubMedGoogle Scholar
  • 85 Self WH, Balk RA, Grijalva CG. , et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017; 65 (02) 183-190
    CrossrefPubMedGoogle Scholar
  • 86 Self WH, Grijalva CG, Williams DJ. , et al. Procalcitonin as an early marker of the need for invasive respiratory or vasopressor support in adults with community-acquired pneumonia. Chest 2016; 150 (04) 819-828
    CrossrefPubMedGoogle Scholar
  • 87 Mandell LA, Wunderink RG, Anzueto A. , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    CrossrefPubMedGoogle Scholar
  • 88 So W, Crandon JL, Nicolau DP. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus . Intern Emerg Med 2016; 11 (04) 545-551
    CrossrefPubMedGoogle Scholar
  • 89 Nguyen HM, Jones RN. Treatment of methicillin-susceptible Staphylococcus aureus osteoarticular and prosthetic joint infections: using the oxacillin minimum inhibitory concentration to guide appropriate ceftriaxone use. Clin Infect Dis 2013; 57 (01) 161-162
    PubMedGoogle Scholar
  • 90 Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents 2014; 44 (03) 235-241
    CrossrefPubMedGoogle Scholar
  • 91 Sader HS, Farrell DJ, Flamm RK, Jones RN. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). J Antimicrob Chemother 2015; 70 (07) 2053-2056
    PubMedGoogle Scholar
  • 92 File Jr TM, Low DE, Eckburg PB. , et al; FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii19-iii32
    PubMedGoogle Scholar
  • 93 Eljaaly K, Wali H, Basilim A, Alharbi A, Asfour HZ. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis. Int J Antimicrob Agents 2019; 54 (02) 149-153
    CrossrefPubMedGoogle Scholar
  • 94 Wunderink RG, Mendelson MH, Somero MS. , et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus . Chest 2008; 134 (06) 1200-1207
    CrossrefPubMedGoogle Scholar
  • 95 Torell E, Molin D, Tano E, Ehrenborg C, Ryden C. Community-acquired pneumonia and bacteraemia in a healthy young woman caused by methicillin-resistant Staphylococcus aureus (MRSA) carrying the genes encoding Panton-Valentine leukocidin (PVL). Scand J Infect Dis 2005; 37 (11-12): 902-904
    CrossrefPubMedGoogle Scholar
  • 96 Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128 (04) 2732-2738
    CrossrefPubMedGoogle Scholar
  • 97 Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 (Suppl. 01) S31-S34
    PubMedGoogle Scholar
  • 98 Tacconelli E, De Angelis G. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr Opin Pulm Med 2009; 15 (03) 218-222
    CrossrefPubMedGoogle Scholar
  • 99 Fujisaki N, Takahashi A, Arima T. , et al. Successful treatment of Panton-Valentine leukocidin-expressing Staphylococcus aureus-associated pneumonia co-infected with influenza using extracorporeal membrane oxygenation. In Vivo 2014; 28 (05) 961-965
    PubMedGoogle Scholar
  • 100 He H, Wang H, Li X. , et al. Successful rescue combination of extracorporeal membrane oxygenation, high-frequency oscillatory ventilation and prone positioning for the management of severe methicillin-resistant Staphylococcus aureus pneumonia complicated by pneumothorax: a case report and literature review. BMC Pulm Med 2017; 17 (01) 103
    CrossrefPubMedGoogle Scholar
  • 101 Noah MA, Dawrant M, Faulkner GM. , et al. Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: experience and outcome. Crit Care Med 2010; 38 (11) 2250-2253
    CrossrefPubMedGoogle Scholar
  • 102 Redi D, Raffaelli CS, Rossetti B, De Luca A, Montagnani F. Staphylococcus aureus vaccine preclinical and clinical development: current state of the art. New Microbiol 2018; 41 (03) 208-213
    PubMedGoogle Scholar
  • 103 Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 2009; 77 (07) 2712-2718
    CrossrefPubMedGoogle Scholar
  • 104 Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci 2016; 37 (03) 231-241
    CrossrefPubMedGoogle Scholar
  • 105 Gauduchon V, Cozon G, Vandenesch F. , et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189 (02) 346-353
    CrossrefPubMedGoogle Scholar
  • 106 De la Calle C, Morata L, Cobos-Trigueros N. , et al. Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis 2016; 35 (03) 497-502
    CrossrefPubMedGoogle Scholar
  • 107 Sicot N, Khanafer N, Meyssonnier V. , et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia—results of a prospective observational study. Clin Microbiol Infect 2013; 19 (03) E142-E148
    CrossrefPubMedGoogle Scholar